Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Nov 08, 2023 9:45am
126 Views
Post# 35723376

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Filing today

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Filing todayGod bless you as well!

I think you misunderstood me and perhaps you have not been reading my other posts. If you are somehow under the impression that I think the THTX board served shareholder interests well, I am just not sure how you got there!
canadapiet wrote:
"It is worth remembering that Marathon likely cares less about shareholders interests than the board of THTX does"

Really???? 
You are becoming "the clown" of the message board man! 
When did the board of TH take care of the shareholders??????
Like i (and many others) pointed out a long time before: THEY DON'T CARE ABOUT THE SHAREHOLDERS!!!! 
Man, look at all they did the last years............., there are people put in jail for less!! 

Amen! (may God bless you....., but i think he is in another "universe")


 
RE:RE:RE:RE:RE:RE:RE:RE:New Filing today
The chances of an adjusted EBITDA breech seem low, but if it did happen I suspect that would open the door for MArathon to come in and grab the assets. I am not sure what recourse THTX might have in such a situation. Previously, the best way for Marathon to get their cash back was to renegotiate the loan after a breech, earn some extra fees and then let THTX run its business to generate teh needed cah. With $60 million in loans outstnading and around $48 million in cash on the balance sheet right now, the way Marathon may look at another breech, should it even happen, may be diffferent. For example, if there are good results on cancer recently reported, then taking the company's assets versus renegotiating might produce a bonanza for Marathon.

It is worth remembering that Marathon likely cares less about shareholders interests than the board of THTX does. So, I am wondering what PWIB, who has some experience in this area, might think about this admittedly remote risk.


<< Previous
Bullboard Posts
Next >>